Botulinum toxin A injection for spasticity in diplegic-type cerebral palsy

Journal of Child Neurology

Volumn 21, Issue 12, 2006, Pages 1009-1012

  El, Ozlem ^a   Peker, Ozlen ^a   Kosay, Can ^a   Iyilikci, Leyla ^a   Bozan, Ozgur ^a   Berk, Haluk ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ABSENCE OF SIDE EFFECTS; ANKLE; ARTICLE; CEREBRAL PALSY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FUNCTIONAL ASSESSMENT; GAIT; GASTROCNEMIUS MUSCLE; GONIOMETRY; HAMSTRING; HUMAN; KNEE FUNCTION; MALE; MODIFIED ASHWORTH SCALE; MOTOR CONTROL; MOTOR PERFORMANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANGE OF MOTION; RATING SCALE; SPASTICITY; STATISTICAL SIGNIFICANCE;

BOTULINUM TOXIN TYPE A; CEREBRAL PALSY; CHILD; CHILD, PRESCHOOL; DISABILITY EVALUATION; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MUSCLE CONTRACTION; MUSCLE SPASTICITY; MUSCLE, SKELETAL; NEUROMUSCULAR AGENTS; THIGH; TREATMENT OUTCOME;

EID: 33846378730     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/7010.2006.00225     Document Type: Article

References (22)

1. Goldstein M: The treatment of cerebral palsy: What we know, what we don't know. J Pediatr 2004;145:42-46.
2. Flett PJ: Rehabilitation of spasticity and relaxed problems in childhood cerebral palsy. J Paediatr Child Health 2003;39:6-14.
3. Goldstein M, Harper DC: Management of cerebral palsy; equinus gait. Dev Med Child Neurol 2001;43:563-569.
4. Boyd R, Graham HK: Botulinum toxin in the management of children with cerebral palsy: Indications and outcome. Eur J Neurol 1997;4:15-22.
5. Simpson LL: Current concepts on the mechanism of action of clostridial neurotoxins, in DasGupta BR (ed): Botulinum and Tetanus Toxins. New York, Planum Press, 1993, 5-15.
6. Bohannon RW, Smith MB: Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987;67:206-207.
7. Boyd RN, Graham HK: Objective measurement of clinical finding in the use of botulinum toxin type A for the management of children with cerebral palsy. Eur J Neurol 1999;6(Suppl 4):522-535.
8. Russel DJ, Rosenbaum PL, Cadman DT, et al: The gross motor function measure: A means to evaluate the effects of physical therapy. Dev Med Child Neurol 1989;31:341-352.
9. Koman LA, Mooney JF, Smith BP, et al: Management of spasticity in cerebral palsy with botulinum A toxin: Report of preliminary, randomized, double blind trial. J Pediatr Orthop 1994;14:299-303.
10. Rodda J, Graham HK: Classification of gait patterns in spastic hemiplegia and spastic diplegia: A basis for a management algorithm. Eur J Neurol 2001;8(Suppl 5):98-108.
11. Gaebler-Spira D, Revivo G: The use of botulinum toxin in pediatric disorders. Phys Med Rehabil Clin N Am 2003;14:703-725.
12. Koman LA, Mooney JF, Smith B, et al: Management of cerebral palsy with botulinum A toxin: Preliminary investigation. J Pediatr Orthop 1993;13:489-495.
13. Koman LA, Brashear A, Rosenfeld S, et al: Botulinum toxin type A neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: A multicenter open-label clinical trial. Pediatrics 2001;108:1062-1071.
14. Uhbi T, Bhakta BB, Ives HL, et al: Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Arch Dis Child 2000;83:481-487.
15. Wong V: Use of botulinum toxin injection in 17 children with cerebral palsy. Pediatr Neurol 1998;18:124-131.
16. Mall V, Kirscher J, Linder M, et al: Botulinum toxin A in children with cerebral palsy: Evaluation of therapy using the Pediatric Evaluation of Disability Inventory. J Pediatr Neurol 2003;1:29-34.
17. Slawek J, Klimont L: Functional improvement in cerebral palsy patients treated with botulinum toxin A injections: Preliminary results. Eur J Neurol 2003;10:313-317.
18. Berweck S, Heinen F: Use of botulinum toxin in pediatric spasticity (cerebral palsy). Mov Disord 2004;19(Suppl 8):162-167.
19. Cosgrove AF, Graham HK: Botulinum toxin A prevents the development of contractures in hereditary spastic mouse. Dev Med Child Neurol 1994;36:379-385.
20. Graham HK, Aoki KR, Autti-Rono I, et al: Recommendations for use of botulinum toxin type A in the management of cerebral palsy, review. Gait Posture 2000;11:67-79.
21. Wong V: Use of botulinum toxin injection in children with spastic cerebral palsy. Pediatr Neurol 1998;18:124-131.
22. Pidcock FS: The emerging role of botulinum toxin in the treatment of cerebral palsy. J Pediatr 2004;145:33-35.